The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses
Open Access
- 22 January 2015
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 137 (4) , 819-825
Abstract
We previously reported that the prognosis of microsatellite instability high (MSI-H) gastric cancer is similar to that of MSI-low/microsatellite stable (MSI-L/MSS) gastric cancer. The reason for this seemed to be related to the effects of chemotherapy. To verify this hypothesis, we expanded the study population and reanalyzed the prognosis of MSI-H gastric cancer. Data from 1,276 patients with Stage II and III gastric cancer who underwent gastrectomy with curative intent between January 2005 and June 2010 were reviewed. The prognosis of MSI-H tumors in comparison with MSI-L/MSS tumors was analyzed, according to the administration of chemotherapy and other clinicopathologic features. A total of 361 (28.3%) patients did not receive chemotherapy (MSI-H = 47 and MSI-L/MSS = 314), whereas 915 (71.7%) patients did receive chemotherapy (MSI-H = 58 and MSI-L/MSS = 857). The hazard ratio of MSI-H versus MSI-L/MSS was 0.49 (95% confidence interval: 0.26–0.94, p = 0.031) when chemotherapy was not received and 1.16 (95% confidence interval: 0.78–1.71, p = 0.466) when chemotherapy was received. In subgroup analyses, the prognosis of MSI-H was better in Stage III, women, with lymph node metastasis, and undifferentiated histology subgroups when chemotherapy was not received. However, in patients treated with chemotherapy, prognosis was worse for MSI-H tumors in Stage III, undifferentiated histology, and diffuse type subgroups of gastric cancer. In conclusion, MSI-H tumors were associated with a good prognosis in Stage II and III gastric cancer when patients were treated by surgery alone, and the benefits of MSI-H status were attenuated by chemotherapy.Keywords
Funding Information
- the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1020390)
- the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1320360)
This publication has 26 references indexed in Scilit:
- Is microsatellite instability a prognostic marker in gastric cancer?: A systematic review with meta-analysisJournal of Surgical Oncology, 2014
- Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian seriesAnnals of Oncology, 2012
- Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5‐FU based chemotherapy after R0 resectionInternational Journal of Cancer, 2011
- Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial CarcinomaJournal of Clinical Oncology, 2006
- Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancersSurgery, 2006
- Systematic Review of Microsatellite Instability and Colorectal Cancer PrognosisJournal of Clinical Oncology, 2005
- Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instabilityThe Journal of Pathology, 2002
- Distinct Clinical Features and Outcomes of Gastric Cancers with Microsatellite InstabilityLaboratory Investigation, 2002
- Microsatellite instability in synchronous gastric carcinomasInternational Journal of Cancer, 2001
- Microsatellite instability is a genetic marker for the development of multiple gastric cancersInternational Journal of Cancer, 2000